Results 301 to 310 of about 775,670 (354)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Nature Reviews Clinical Oncology, 2021
Alex Friedlaender, Vivek Subbiah, Alessandro Russo   +2 more
exaly   +2 more sources

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

New England Journal of Medicine, 2023
BACKGROUND Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
D. Planchard, P. Jänne, Ying Cheng, J. Yang, N. Yanagitani, Sang-we Kim, S. Sugawara, Yan Yu, Yun Fan, S. Geater, K. Laktionov, Chee Khoon Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, I. Andrasina, J. Goldman, D. Ghiorghiu, Y. Rukazenkov, Alex Todd, K. Kobayashi   +20 more
semanticscholar   +1 more source

EGFR and anti-EGFR nanobodies: review and update

Journal of Drug Targeting, 2020
Targeted therapy is one of the favourable methods used in cancer treatment. Several recombinant proteins and small-molecules used for this aim include monoclonal antibodies, antibody fragments and peptides. Nanobody (Nb) is a camelid antibody fragment that is very effective in targeted therapy.
Jafar Sharifi, Mohammad Reza Khirehgesh, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.

Current Topics in Medicinal Chemistry, 2020
The epidermal growth factor receptor (EGFR) belongs to ERBB family of tyrosine kinase receptor. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development.
D. Sabbah, Rima Hajjo, K. Sweidan
semanticscholar   +1 more source

EGFR-targeted therapy

Experimental Cell Research, 2011
Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds.
Vecchione L, Jacobs B, Normanno N, CIARDIELLO, Fortunato, Tejpar S.   +4 more
openaire   +3 more sources

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

The Lancet Respiratory Medicine, 2019
BACKGROUND The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel ...
M. Reck, T. Mok, M. Nishio, R. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodríguez-Abreu, D. Moro-Sibilot, C. Thomas, F. Barlesi, G. Finley, Anthony Lee, S. Coleman, Yu Deng, M. Kowanetz, G. Shankar, W. Lin, M. Socinski   +19 more
semanticscholar   +1 more source

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2019
BACKGROUND Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented.
K. Nakagawa, E. Garon, T. Seto, M. Nishio, S. Ponce Aix, L. Paz-Ares, C. Chiu, Keunchil Park, S. Novello, E. Nadal, F. Imamura, K. Yoh, J. Shih, K. Au, D. Moro-Sibilot, S. Enatsu, A. Zimmermann, B. Frimodt-Moller, C. Visseren-Grul, M. Reck   +19 more
semanticscholar   +1 more source

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

The Lancet Oncology, 2020
BACKGROUND Preclinical data suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET TKIs are a possible treatment for EGFR mutation-positive lung cancers with MET-driven acquired resistance. Phase 1 safety data of savolitinib (also known as AZD6094,
L. Sequist, Ji-Youn Han, M. Ahn, B. Cho, H. Yu, Sang-We Kim, J. Yang, J. Lee, W. Su, D. Kowalski, S. Orlov, M. Cantarini, R. Verheijen, A. Mellemgaard, L. Ottesen, P. Frewer, X. Ou, G. Oxnard   +17 more
semanticscholar   +1 more source

Understanding eGFR

Independent Nurse, 2007
A four part presentation covering the significance of estimated glomerular filtration rate and how to use the test to diagnose chronic kidney disease
Donal O'Donoghue, Ian Wilkinson
openaire   +1 more source